Key Highlights
- SpectraWAVE raises $50M in Series B led by Johnson & Johnson Innovation – JJDC, Inc.
- HyperVue™ Imaging System integrates DeepOCT and NIRS to improve coronary stenting procedures.
- Funding supports commercial expansion and product development, enhancing care for CAD patients.
- Backed by leading MedTech investors including S3 Ventures, Lumira Ventures, and more.
Source: Business Wire
Notable Quote
- “Intravascular imaging guidance is backed by a wealth of randomized clinical trials (RCT) and recently collated in a meta-analysis of 22 RCT studies and approximately 16,000 patients published this year in The Lancet, demonstrating significantly improved outcomes for patients undergoing coronary stenting. This financing, supported by leading MedTech investors, will support our commercial expansion to bring HyperVue to more patients.” — Eman Namati, Ph.D., Chief Executive Officer at SpectraWAVE
SoHC's Take
SpectraWAVE’s $50M Series B funding marks a pivotal step in revolutionizing coronary artery disease treatment. With HyperVue™ Imaging System’s integration of DeepOCT and NIRS, the company is positioned to redefine intravascular imaging. The system’s AI-driven workflow and no-flush catheter prep significantly enhance procedural efficiency, addressing long-standing compromises in image resolution and depth. SpectraWAVE’s expansion is well-timed as the adoption of advanced imaging technologies for coronary stenting grows, driven by strong clinical evidence and international guidelines. This funding allows SpectraWAVE to advance both its product and commercial presence, potentially making a significant impact on patient outcomes globally.
